MedTrace Logo

Feasibility and Safety Study of LAmbre Left Atrial Appendage Occluder

NCT01920412 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-08-07

No results posted yet for this study

Summary

This study mainly evaluated the feasibility and safety of LAmbre Left Atrial Appendage Occluder which is to prevent ischemic stroke caused by atrial fibrillation(AF).

Conditions

Interventions

DEVICE

LAmbre Left Atrial Appendage(LAA) Occluder

Implanting the LAmbre Left Atrial Appendage Occluder to close the left atrial appendage

Sponsors & Collaborators

  • Lifetech Scientific (Shenzhen) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yat-Yin YY Lam, MD · Prince of Wales Hospital, Shatin, Hong Kong

  • Muhammad Munawar, MD · Binawaluya Hospital, Indonesia

  • Lan Hieu Nguyen, MD · Hanoi Heart Hospital, Vietnam

  • Yan Yao, MD · Chinese Academy of Medical Sciences, Fuwai Hospital

  • Congxin Huang, MD · Renmin Hospital of Wuhan University,China

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-10-31
Completion
2014-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01920412 on ClinicalTrials.gov